Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

BACKGROUND: In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC). Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients...

Full description

Saved in:
Bibliographic Details
Published in:Ann Oncol
Main Authors: Shaw, A T, Riely, G J, Bang, Y -J, Kim, D -W, Camidge, D R, Solomon, B J, Varella-Garcia, M, Iafrate, A J, Shapiro, G I, Usari, T, Wang, S C, Wilner, K D, Clark, J W, Ou, S -H I
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637370/
https://ncbi.nlm.nih.gov/pubmed/30980071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz131
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items